




# Novel long-acting opthamology drugs



PASylation®, a biological alternative to PEGylation, is a superior technology to design intravitreal long-acting drugs to treat back of the eye diseases and to improve patient's quality of life. The hydrated, disordered PAS polypeptide chain adopts an expanded hydrodynamic volume and strongly increases the intraviteal half-life of the therapeutic. There is no need for a potential inflammatory Fc-part. Furthermore, PAS fusion proteins can be produced in a cheap way, at high yield using industry-leading expression technology platforms. In addition, PAS can be can be utilized as a linker to generate innovative 3rd generation biologics with bior multispecificity.



# Expanded hydrodynamic volume



- Slow vitreal clearance
- Reduced injection frequencies



### Genetic PAS fusion enables:

- Creation of bi-/multispecifics
- Cheap manufacturing
- Homogenous product

# No Fc region:

- No inflammatory mediator
- No complement activation
- Excellent patient compliance
- PAS polypeptides characteristics:
- Non-toxic
- Biodegradable
- Excellent tolerance

#### **Related Publications & Press releases:**



Eskandarpour M. et al. (2021) Leukotriene B 4 and Its Receptor in Experimental Autoimmune Uveitis and in Human Retinal Tissues: Clinical Severity and LTB 4 Dependence of Retinal Th17 Cells. Am. J. Pathol. 191, 320-334.



Eskandarpour M.et al. (2021) Immune-Mediated Retinal Vasculitis in Posterior Uveitis and Experimental Models: The Leukotriene (LT)B4-VEGF Axis. Cells 10, 396.



NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE): Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

## Partnering contact:

XL-protein GmbH Claus Schalper Lise-Meitner-Str. 30 85354 Freising Germany

Phone: +49 (0) 8161 53730-90 Fax: +49 (0) 8161 53730-99 E-mail: bd@xl-protein.com

Web: www.xl-protein.com